Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Anti-neoplastic combinations and dosing regimens using CDK4/6 inhibitor compounds to treat Rb-positive tumors

Anti-neoplastic combinations and dosing regimens using CDK4/6 inhibitor compounds to treat Rb-positive tumors

US Patent 11446295 · Granted Sep 20, 2022

Estimated economic value: $11,157,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Morphic forms of trilaciclib and methods of manufacture thereof2025
Morphic forms of trilaciclib and methods of manufacture thereof2025
Systems and methods for optimal path determination using contraction hierarchies2025
G1T38 superior dosage regimes2025
Substituted 1′,2′-dihydro-3′H-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2025
Treatment of Rb-negative tumors using topoisomerase inhibitors in combination wi2025
Treatment of Rb-negative tumors using topoisomerase inhibitors in combination wi2025
Treatment of Rb-negative tumors using topoisomerase inhibitors in combination wi2025
Treatment of Rb-negative tumors using topoisomerase inhibitors in combination wi2025
Synthesis of 1,4-diazaspiro[5.5]undecan-3-one2025
Patient-specific medical devices and additive manufacturing processes for produc2025
Morphic forms of trilaciclib and methods of manufacture thereof2024